Testosterone Science

FDA, Regulation and Guidelines

The FDA Just Rewrote the Rules on Testosterone.

Grade Incomplete reporting Categories: Testosterone in men >> FDA, regulation and guidelines

Specific Claim Evaluated

Low testosterone that comes simply from getting older is now recognized as a legitimate, treatable condition under the label.

Primary Research Supporting or Contradicting the Claim

The FDA requested label updates in June 2026 (U.S. Food and Drug Administration, 2026b); the only new indication under consideration is low libido in idiopathic hypogonadism, which requires a supplemental application (U.S. Food and Drug Administration, 2026a). In older men with low testosterone, benefits were limited to sexual function and mood (Snyder et al., 2016).

Corrected Evidence-Based Interpretation

Removal of the age-related limitation of use was requested, not implemented. Removal of a limitation does not create a new indication for age-related decline.

Rationale for Grade

The article reports the TRAVERSE event rates correctly and later states that the change is a proposed labeling update requiring monitoring, which mitigates the error. The quoted sentence nonetheless presents a requested change as an implemented label recognition. The headline ('rewrote the rules') reinforces that impression. The grade reflects an overstatement offset by later qualification.

References

  1. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PMID
    Supporting excerpt: "had a moderate benefit with respect to sexual function"
  2. U.S. Food and Drug Administration. Potential new indication for testosterone replacement therapy. Federal Register. 2026;91 FR 21002. Document 2026-07615. Published April 20, 2026.
    Supporting excerpt: "information in published literature that seems promising"
  3. U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
    Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.